Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
61 hedge funds and large institutions have $116M invested in Stemline Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 14 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
0% more funds holding
Funds holding: 61 → 61 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
32% less capital invested
Capital invested by funds: $172M → $116M (-$55.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.03M |
| 2 |
Renaissance Technologies
New York
|
+$1.55M |
| 3 |
Goldman Sachs
New York
|
+$1.16M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$1.02M |
| 5 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$869K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.3M |
| 2 |
Morgan Stanley
New York
|
-$784K |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$391K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$357K |
| 5 |
QF
QVT Financial
New York
|
-$328K |
STML Hedge Fund Activity: Q2 2014 in Review
61 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2014, worth a combined $116M — down 32% from $172M a quarter earlier.
Fund positioning in STML was balanced in Q2 2014: 14 funds opened new positions, 14 closed out, 27 added to existing stakes and 12 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $3.03M. The largest seller was T. Rowe Price Associates, cutting an estimated $11.3M.
- 61 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $116M of Stemline Therapeutics, Inc. stock for Q2 2014, down 32% quarter-over-quarter.
- 14 funds opened new Stemline Therapeutics, Inc. positions in Q2 2014 and 14 closed out, a net change of 0 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q2 2014 was Eventide Asset Management, an estimated $3.03M added.
- The largest Stemline Therapeutics, Inc. seller in Q2 2014 was T. Rowe Price Associates, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2014.